PROSPECTIVE OBSERVATIONAL COHORT STUDY OF PATIENTS WITH METASTATIC HER-2+ BREAST CANCER AT RISK OF CARDIAC TOXICITY

COGNITIVE TRAINING FOR CANCER RELATED COGNITIVE IMPAIRMENT IN BREAST CANCER SURVIVORS: A MULTI-CENTER RANDOMIZED DOUBLE- BLINDED CONTROLLED TRIAL

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

PHASE 2 TRIAL OF FULVESTRANT AND BINIMETINIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER WITH A FRAMESHIFT OR NONSENSE MUTATION OR GENOMIC DELETION IN NF1

A Phase II Randomized Trial of Olaparib Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Selective Use of ALND in cT1-2N1 HR+/HER2- Breast Cancer Patients with 1 or 2 Positive Sentinel Lymph Nodes Undergoing Upfront Surgery and Adjuvant Radiation: A Prospective Study

THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), A DOUBLE-BLINDED, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III